Introduction
Although ovarian cancer is less frequent than breast cancer, it is often fatal due to little understanding of the disease and lack of approaches for early detection. It is the fourth common cause of cancer mortality and a serious threat to American women (Wingo et al., 1995) . The majority (about 90%) of malignant ovarian tumors arise from the specialized mesothelial cells, which cover the ovarian surface in a single cell layer to form the surface epithelium (Bell, 1991; Berchuck and Carney, 1997; Bast et al., 1993; Godwin et al., 1993) . The tumor mass that developed inside the ovary consists of cancerous cells derived either from the proliferative surface epithelial cells (mesothelial cells) that invade the ovarian cortex or from the transformed surface epithelial cells of inclusion cysts which are trapped within the cortex during ovulation or remodeling of the ovarian surface. The surface epithelial cells have an important function in ovulation, and the cells undergo a rapid phase of growth following each ovulation to repair the surface wound (Godwin et al., 1993) . Although the etiology of the surface epithelial ovarian cancer is not yet clear, it is thought that proliferation of the ovarian surface epithelial cells through repetitious cycle of ovulations, and hence associated genetic mutations, contribute to the cancer (Godwin et al., 1993) .
The genetic mutations in ovarian cancer have been studied, as detailed in several reviews (Berchuck and Carney, 1997; Bast et al., 1993; Godwin et al., 1993; Zhou et al., 1988) : the p53 tumor suppressor gene is frequently (about 50%) mutated in late stage cancer; herr-2/neu and c-Myc over-expression is associated with about 30% of ovarian tumors; Ras activations have been found, but point mutations of Ras genes are not a common event in ovarian cancer. Additional and critical genetic mutations, especially those involved in early stages of ovarian tumor development, remain to be identi®ed. Although most ovarian malignancies are sporadic, there is a common genetic element involved in ovarian cancer. The risk of ovarian cancer is high in families with a history of breast cancer and vice versa (Szabo and King, 1995) . Linkage analysis of familial cancer and positional cloning has led to the identification of the breast and ovarian cancer gene, BRCA1 (Szabo and King, 1995; Miki et al., 1994) , but the role of this gene in sporadic cancers has not been con®rmed (Futreal et al., 1994) . Other approaches such as dierential displaying by comparing genetic information of normal and tumor cells, and studies of the cellular mitogenic mechanisms are now being used in attempts to ®nd gene mutations which contribute to ovarian cancer (Knudson, 1993) .
One of the candidates uncovered by dierential displaying and signal transduction studies is Disabled-2 (Dab2). Dab2 cDNA, which encodes a 96 kd mitogenresponsive phosphoprotein was cloned from a mouse macrophage library . Dab2 protein exhibits sequence homology with the Drosophila Disabled (dDab) (Gertler et al., 1989 (Gertler et al., , 1993 Hoffmann, 1991) , and is probably a mammalian homolog. The structure of Dab2 includes a phosphotyrosine interacting domain (PID or PTB) (Bork and Margolis, 1995; Kavanaugh and Williams, 1994 ) and a prolinerich SH3-binding domain (Ren et al., 1993) , suggesting a function in mediating protein-protein interactions. Dab2 is rapidly phosphorylated when cells are exposed to growth factors or mitogen , suggesting a role in mitogenic signaling. Studies have shown that Dab2 binds to the adaptor protein Grb2, and have suggested that Dab2 may negatively regulate cell growth by down-regulating Ras activation in its binding and sequestering of Grb2 from Sos/Grb2 complex . The relevance of Dab2 to ovarian cancer was also suggested by a dierential displaying study which showed that the expression of Dab2 is lost in ovarian carcinomas (Mok et al., 1994; Wong et al., 1993) . In the study, a 782 bp human cDNA fragment, DOC-2 (Dierentially expressed in Ovarian Carcinomas 2) was isolated by dierential RNA display. The sequence identity indicates that the DOC-2 DNA fragment is part of the human Dab2 (Albertsen et al., 1996) . The expression of Dab2 was found absent in all ovarian tumor cells and tissues examined, but was present in normal ovarian epithelial cell lines and tissues (Mok et al., 1994; Wong et al., 1993 ). Dab2 appears to have a role in growth factor mitogenic signal transduction , hence the loss of Dab2 expression in tumor cells may alter cellular mitogenic signaling pathway and contribute to malignancy. Especially, frequent homozygous deletions of Dab2 gene were uncovered in human ovarian tumors, further implicating the involvement of Dab2 mutations and loss of expression in tumorigenicity (Fazili et al., 1998) . In this study, we have examined the expression pattern of Dab2 in both human and mouse tissues using Western and Northern blot analysis, and in normal and cancerous ovarian tissues using immunohistological technique.
Results

Tissue distribution of Dab2
Dab2 is expressed in most of the mouse tissues examined, including heart, lung, liver, skeletal muscle, and is particularly high in kidney (Figure 1a) . Human Dab2 is also widely expressed in tissues including spleen, thymus, prostate, testis, small intestine, and is particularly abundant in ovary (Figure 1b) . However, Dab2 expression was not seen in peripheral blood leukocytes. Two or three mRNA species were detected for Dab2 in both human and mouse tissues, which are known to be splicing variants . Because our interest is to elucidate the function of Dab2 in cancer of the breast and ovary, we have examined Dab2 expression in these tissues. Frozen samples of human breast and ovarian tissues from surgery were obtained from the Emory University Hospital, and were evaluated by pathologists to be non-tumor tissue samples. In a Northern blot analysis, Dab2 was found to be highly expressed in these tissues, compared to MCF-10 which are immortalized, non-tumorigenic human breast epithelial cells (Figure 1c ).
Dab2 expression in breast and ovarian tumor cell lines
Human Dab2 mRNA has been found absent or suppressed in ovarian tumor cell lines and tissues, and is present in normal ovarian surface epithelial cells and tissues analysed by Northern blotting using the isolated 782 base pair cDNA fragment (also known as DOC-2) as probe (Mok et al., 1994; Wong et al., 1993) . We also con®rmed this observation by employing Western blot using our speci®c anti-Dab2 antibodies (anti-M2) in a Western blot analysis (Figure 2 , upper panel), we detected the expression of the 96 kd Dab2 protein in breast epithelial cells MCF-10 and Hs578.Bst, and non-tumorigenic lung epithelial cells, Lung N (ATCC, CR 7000, Hs.1Lu), but the protein is absent in tumor cell lines including: MCF-7, MDA-MB-231, MDA-MB-468, SK-Br-3, T47-D breast cancer cells; and CAOV-3, NIH:OVCAR-3, OV1063, PA-1, SW636 ovarian cancer cells. Although human Figure 1 Dab2 tissue distribtion and its expression. (a) Expression of Dab2 in mouse tissues. A multiple mouse tissue blot containing mRNA from heart, brain, spleen, lung, liver, smooth muscle, kidney and testis (Clontech, Inc., mouse large organ blot, 2 mg mRNA per lane) was hybridized with labeled mouse Dab2 cDNA probe (see Materials and methods). The probe was labeled with digoxigenin epitope using the Genus Nucleic Acid Labeling and Detection kit and the signals were visualized by chemiluminescence. All lanes contain comparable amount of mRNA as shown by a Northern analysis with a human beta-actin probe. Actin control was used as loading indication. (b) Expression of Dab2 in human tissues. A multiple human tissue blot containing mRNA from spleen, thymus, prostate, testis, ovary, small intestine, colon and blood leukocyte (Clontech, Inc., human small organ blot, 2 mg mRNA per lane) was hybridized with a human 0.4 kb Dab2 cDNA probe as above. (c) Expression of Dab2 in human breast and ovarian tissues. The total RNA was isolated by homogenization of the minced frozen samples of human breast and ovarian tissues with QIAshredder TM kit, and extraction with RNeasy kit (Qiagen). The total RNA (10 mg) was subjected to Northern blot analysis. The gel was stained with ethidium bromide to visualize the 28S rRNA to estimate the RNA amount loaded (lower panel). Blots were hybridized with human Dab2 cDNA probe labeled with 5 ml a- (Figure 2, lower panel) . Dynamin, a structural protein involved in endocytosis, was chosen as a control for protein loading because of its similar molecular weight (100 kd) as Dab2 (96 kd), and we found that dynamin, not beta-actin, seems to correlate very well with cellular protein content in all cells tested.
Thus, similar to the previous observations (Mok et al., 1994; Wong et al., 1993) , our studies, using newly developed speci®c antibodies, show that Dab2 expression is eliminated in most of the breast and ovarian cancer cells. There are no non-speci®c protein bands recognized by the anity puri®ed antibodies (anti-M2) in the blot of total cell lysate ( Figure 2 , upper panel), indicating the high speci®city of our antibodies to the Dab2 protein.
Expression of Dab2 in ovarian epithelium
The expression status of a protein is often altered in established cell lines due to adaptation to the tissue culture condition, and may not, therefore, represent expression in situ. Thus, with speci®c antibodies prepared, we further analysed the expression of Dab2 in human tissue sections. First, we carried out antibody titration experiments, and found that we were able to stain breast epithelial cells in a normal human breast lobule section with little background staining in the stroma (Figure 3a) . The staining was reduced/abolished by including 20 mM of the peptide antigen (M2-peptide) in the incubation, indicating speci®city of the staining for Dab2 protein ( Figure 3b) .
In this study, we have chosen to focus on analysis of Dab2 expression in ovaries and ovarian tumors. We have stained Dab2 in tissue sections from ®ve dierent human ovaries, and found that Dab2 staining is most intense in the epithelial cells of the ovarian surface layer. An example of a typical staining pattern is shown in Figure 3c , d and e. The surface epithelial cell layers in ovarian invaginations and inclusion cysts were also stained ( Figure 3d ). The Dab2 staining is largely cytoplasmic, as shown in a higher magni®cation (Figure 3e ). The ovarian stroma and other structures (blood vessels, follicles, and corpus luteum) are largely unstained (data not shown). Macrophage and fibroblast-like cells distributed in the stroma, are stained ( Figure 3 ). It is known that macrophage and ®broblast cells express Dab2 (Xu et al., 1995, and Xu, unpublished observation) .
In some tumor tissues, pre-malignant, recognizable surface epithelial layer was present on the edges of the tumor mass. Several of these examples are shown in Figure 3f , g and h, showing immunostaining for Dab2 in ovarian surface epithelium of part of a contiguous tumor. Some normal looking ovarian epithelial layers around the tumor mass show strong Dab2 staining in the epithelial cells (Figure 3f ), while hyperproliferative surface epithelium in another ovarian tumor showed no Dab2 staining ( Figure 3g ). In this section ( Figure  3g ), the surface epithelial cells are largely unstained, however, the dispersed macrophage/®broblast staining in the stroma is evident, and serves as an internal positive control for the immunohistological staining. Transitional staining (existence of Dab2-positive and Figure 4 , panel (a1, 2) (tumor #3 in Table 1 , serous cystadenocarcinoma), (b1, 2) (tumor #7, papillary serous adenocarcinoma, and (c1, 2) (tumor #26, endometrioid adenocarcinoma), showed no Dab2 staining in tumor cells, while macrophage/®broblast cells in the stroma displayed Dab2 staining. An example of strong Dab2 staining in tumor cells is shown in Figure 4d1 , 2 a section of an invasive ovarian tumor (tumor #5, papillary serous adenocarinoma). Therefore, our immunostaining studies of ovarian tumor tissues showed marked decrease or complete loss of Dab2 expression in a large percentage (85%) of the tumors. The results of this study are listed in Table 1 . The loss of Dab2 expression does not correlate with the progression of a tumor, since the percentage of Dab2-positive grade 1 and 2 tumors is not higher than that of Dab2-positive grade 3 tumors. The absence of correlation between progressive loss of Dab2 expression and tumor grade suggests that loss of Dab2 is an early event. In tumors which express Dab2 protein, the mutational event may reside in another protein in the same regulatory pathway in which Dab2 functions. Also, it is possible that the immunoreactive Dab2 protein expressed may carry an inactivating mutation.
Loss of Dab2 expression is closely correlated with morphological transformation of ovarian surface epithelial cells About 90% of ovarian cancers are of epithelial origin, and all the tumors studied here were derived from the ovarian surface epithelial. We have surveyed tumors in which normal ovarian surface epithelium coexists with dysplastic cells, and found a close correlation between loss of Dab2 and morphological changes of the surface epithelial cells. An example is shown in Figure 4e1 , 2, a Dab2 immunostaining of an ovarian papillary serous cystadenocarcinoma. In this tumor, Dab2 staining is absent in the epithelial tumor cells but present in stromal macrophage and ®broblast cells. In a contiguous ovarian surface epithelial layer linking normal and dysplastic tissues (arrow in Figure 4e1 ), Dab2 is observed to express in normal ovarian surface epithelial cells (Figure 4e2 , brown staining surface epithelial layer). However, the staining is absent in the dysplastic epithelial cells residing on the surface next to the normal cells. These dysplastic surface epithelial cells are believed to be the precursor of malignant tumor cells. Thus, again, loss of Dab2 seem to be an early event in ovarian tumorigenicity.
Discussion
This study has surveyed the tissue expression pattern of Dab2 by Northern and Western blotting, and examined the cell types expressing Dab2 protein in tissue sections of ovaries and ovarian-derived tumors by immunostaining. Dab2 was found to be expressed (Figure 1) , and was detected in established cell lines including macrophages, ®broblasts, and epithelial cells. In the ovary, Dab2 is intensely expressed in the surface epithelial cells lining the ovarian surface, deep invaginations, and inclusion cysts. Although ovarian epithelial tumors are believed to arise from these surface epithelial cells (Bell, 1991; Berchuck and Carney, 1997; Bast et al., 1993; Godwin Figure 4 Dab2 expression in ovarian tumor cells in tissue sections. A set of 26 formalin-®xed, paran-embedded ovarian tumor tissues blocks were selected. Sections (5 mm) were cut from these blocks for immunostaining with anti-Dab2 antibodies. Normal breast lobule sections were used as positive controls for Dab2 staining. The staining interpretation of the sections was done by three persons (the authors) independently, and the results are listed in Table 1 . Four representative examples are displayed here as (a 1,2), serous cystadenocarcinoma, tumor #3 in Table 1 In some ovarian tumors, histologically normal or less malignant lesions can be seen adjacent to the mass of the malignant tumor cells. These histologically less malignant lesions may exhibit similar genetic alterations, and are precursors for malignant tumors (Zheng et al., 1995) . In several of the examples (Figure 3) , we observed that Dab2 expression was lost or partially lost in the hyperproliferative but histologically benign surface epithelium, indicating that loss of Dab2 expression is an early event in ovarian tumorigenicity. It is possible that loss of Dab2 expression is one of the ®rst signs of tumorigenicity, since morphological change of the surface epithelial cells is closely correlated with loss of Dab2 expression (Figure 4e ). Consistent with an early role of Dab2 loss in tumor development, we did not ®nd a progressive loss of Dab2 correlated with tumor grade (Table 1) .
The understanding of its role in cellular mitogenic signal transduction may reveal the reason why loss of Dab2 expression may be of bene®t to tumor cells, or whether the loss of Dab2 is crucial for cell transformation at all. The domain structure suggests that Dab2 is an adaptor protein involved in protein-protein interaction . The C-terminal proline-rich domain of Dab2-contains Grb2-binding motifs similar to that of the Ras guanine nucleotide exchanger Sos Lim et al., 1994; Wittekind et al., 1994) . It has been shown previously that Dab2 binds Grb2 in vitro and in vivo, competing with Sos . One possibility is that Dab2 sequesters Grb2 from binding to Sos, thus the dissociation of Grb2/Sos complex may reduce Ras activation, which is thought to be a feed-back mechanism for Ras down-regulation (Cherniack et al., 1995; Waters et al., 1995; Buday et al., 1995) . Ras is frequently activated by point mutations in many cancers (Bos, 1989) . However, though Ras mutations occur, they are not common in breast and ovarian cancer (Berchuck and Carney, 1997; Zhou et al., 1988; Bos, 1989; Clark and Der, 1995) . One possibility is that the Ras pathway is activated by elimination of a regulatory such as Dab2, other than mutation of Ras itself (Clark and Der, 1995).
The Dab2 protein has a Drosophila homolog, the Disabled, or dDab (Gertler et al., 1989 (Gertler et al., , 1993 Homann, 1991) , and a mouse isoform or family member, Dab1 (Howell et al., 1997a) . The known functions of these similar proteins may provide clues to the function of Dab2. Genetic analysis in Drosophila embryonic development indicates that Drosophila Abl kinase and Dab may function in the signaling of neuronal adhesion molecule Fasciclin I-mediated homophilic cell-cell interaction, and in the pathways that control the ®nal position of neuron cells (Gertler et al., 1989 (Gertler et al., , 1993 Homann, 1991) . Murine Dab1 has been shown to have a similar function as the Drosophila homolog (Howell et al., 1997a,b; Sheldon et al., 1997; Ware et al., 1997) . Mice with defective Dab1 have a disturbed brain, in which brain neuron cells are disorganized and fail to form discrete layers (Howell et al., 1997b) . The phenotype of Dab1 knockout or mutant mice is similar to reeler mutant mouse (Howell et al., 1997b; Sheldon et al., 1997; Ware et al., 1997) , which has a mutation in reelin gene encoding an extracellular matrix protein . It leads to the suggestion that Dab1 mediates the reelin signal, functioning in positioning the brain cells in the correct location. Dab2 is about 30% homologous in protein sequence to dDab (similar to Dab1), and is 45% identical, or 60% homologous to mouse Dab1. As shown in this study, Dab2 is widely expressed in various tissues and strongly expressed in the surface epithelial layer of ovary; Dab1 is exclusively expressed in brain (Howell et al., 1997a,b) . Therefore, it is likely that Dab2 controls the positioning of the ovarian mesothelial cells of the surface epithelium. The ovarian surface epithelial cells attach to a basement membrane consisting of laminin and collagen (Stenbak and Wasenius, 1985) , and it is not known whether Reelin is expressed in ovary. As clue from the studies of Dab1, one possibility is that Dab2 mediates the signaling of the ovarian surface epithelial cells contacting the extracellular matrix such as the basement membrane, to ensure the correct location of the mesothelial cells on the surface of an ovary. The signals transmitted by Dab2 may be those such as contact inhibition and anchorage-dependency for growth, which prevent the proliferation of the ovarian mesothelial cells beyond a single layer on the surface of an ovary. Dab2 may negatively regulate cell growth by constraining Ras activation by sequestering Grb2 from Grb2/Sos complex. Thus, loss of Dab2 may result in proliferation of ovarian surface epithelial cells in a disorganized fashion, forming premalignant lesions, which is an early step in ovarian tumorigenicity.
Materials and methods
Reagents
Dulbeco's modi®ed Eagle's Medium (DMEM) and cell culture supplements were purchased from Mediatech Inc. (Herndon, VA, USA); Fetal bovine serum (FBS) was obtained from Atlanta Biological (Atlanta, GA, USA). Lipofectamine and serum-free media were purchased from Gibco BRL (Gaithersburg, MD, USA). Oligonucleotide primers and synthetic peptides were synthesized, puri®ed and analysed by the Microchemical Facility of Emory University. Immunostaining kits were purchased from Signet A-gel 10 and columns for anity-puri®cation of rabbit polyclonal antibodies were from Bio-Rad Laboratories (Hercules, CA, USA). QIAshredder TM kit and RNeasy kit for RNA isolation were purchased from Qiagen (Chatsworth, CA, USA). Genius Nucleic Acid Labeling and Detection Kit was from Boehringer Mannheim (Indianapolis, IN, USA) .
[a-32 P]dCTP was from ICN Biochemicals (Irvine, CA, USA). The oligolabeling kit was obtained from Pharmacia Biotech, Inc. (Piscataway, NJ, USA). G418 was purchased from Mediatech, Inc. (Herndon, VA, USA). All other chemicals and reagents were purchased from Sigma Chemical Co. (St. Louis, MO, USA) and Fisher Biotech (Pittsburg, PA, USA), and were of analytical grade.
Cell cultures
Breast and ovarian epithelial tumor and non-tumorigenic cells were obtained from American Type Culture Collection (ATCC) (Rockville, MD, USA). Non-tumorigenic breast cell lines include Hs578.Bst and MCF-10; tumorigenic breast cancer cells include MCF-7, SK-Br-3, T47-D, Hs578.T, and MDA-MB-231. The ovarian tumor cell lines were NIH:OVCAR-3, SKOV-3, CAOV-4, ES-2, PA-1, OV-1063, and SW636. These cells were cultured in DMEM with 10% FBS supplemented with 10 ng/ml EGF, 1% non-essential amino acids, and 100 unit/ml penicillin, 100 mg/ml streptomycin, in a 5% CO 2 incubator at 378C.
Human tissue, tumor samples and sections
All experimental protocols involving usage of human normal and tumor tissues were examined and approved by the Human Investigation Committee of Emory University. Normal and cancerous human breast and ovarian tissue samples were obtained from surgeries performed at Emory University Hospital. Fresh tumor or non-tumor tissues from surgery were`snap-frozen' in liquid nitrogen, following diagnosis and inspection by pathologists. The tissue samples were formalin-®xed and paran-embedded. Sections (5 mm) were cut and adhered to ProbeOn TM Plus charged and precleaned glass slides (Fisher) or aminoalkylsilane coated Silane-Prep TM glass slides (Sigma).
Antibodies
The Dab2 antiserum (anti M-2) was prepared by immunizing rabbits with the N-terminal Dab2 peptide (M2-peptide: MSNEVETSATNGQPDQQA), customized by the Rockland Inc. (Gibertsville, PA, USA). This antiserum recognizes both murine and human Dab2. The antibodies were anitypuri®ed using the M2 peptide conjugated to A-gel 10 matrix. The anity puri®ed antiserum was used for Western blotting. Goat anti-rabbit IgG, conjugated with horseradish peroxidase, was purchased from the Jackson Laboratory (West Grove, PA, USA). Both anity-puri®ed polyclonal anti-M2 antibodies and monoclonal antibody anti-p96 from Transduction Laboratories (Lexington, KY, USA) were used for immunohistological staining. Anti-Dynamin and Sos monoclonal antibodies were from Transduction Laboratories.
Anity-puri®cation of polyclonal anti-Dab2 antibodies
M2-peptide (20 mg) in a 1.5 ml microcentrifuge tube was dissolved in 1 ml of HEPES-buered saline (137 mM NaCl, 50 mM KCl, 100 mM Na 2 HPO 4 , 100 mM HEPES, pH 7.0). Absorbance of an aliquot was recorded at 280 nm to determine peptide concentration. The sample was stored at 48C overnight.
A-gel 10 matrix (2 ± 5 ml) suspension was washed three times with cold 10 mM sodium acetate buer, pH 4.5, to remove isopropranol. The washed gel suspension was poured into a 15 ml polypropylene tube, and mixed with chilled M2-peptide ligand. An additional 1 ml of HEPES-buered saline was also added. The suspension was then mixed by rocking for 2 ± 4 h at room temperature or overnight at 48C. The suspension was packed in a 5 ml Econo-Pac P6 Cartridges (Bio-Rad, Inc.), and allowed to settle down for 2 min. An aliquot of¯ow through buer was collected from the cartridge in a 1.5 ml tube, and absorbance was recorded at 280 nm to calculate the percent coupling of peptide with the gel matrix. The column was rinsed with 25 ml of equilibration buer (150 mM NaCl, 50 mM TrisHCl, pH 8.6) and 10 ml of 1 M high salt buer (1 M NaCl, 10 mM TrisHCl, pH 7.4). The rabbit antiserum was heat-inactivated at 568C for 30 min to destroy the complement factors. The anti-serum (1 ml) was then loaded onto the column and allowed to absorb for 10 min. The anti-serum was allowed to elute and then reloaded back into the column three times to ensure saturation of the anity gel matrix with antibodies. Unbound proteins were removed by washing the column with 25 ml of the high salt buer and 25 ml of equilibration buer. The column was then washed with 5 ml deionized water. Finally, the antibodies were eluted using 5 ml of Glycine-HCl buer (100 mM glycine, 150 mM NaCl, adjusted to pH to 2.2 with HCl) containing 10% ethylene glycol. The eluant containing antibodies was immediately neutralized with 2 M TrisCl (pH 8.8). An aliquot was taken to estimate protein concentration using Bio-Rad protein assay according to the manufacturer's instructions. Using this puri®cation method, about 130 mg protein was recovered from 1 ml of antiserum. The column was used sequentially for three times. The aliquots of anity-puri®ed antibody preparation were stored at 7208C for future use.
Western blot analysis
About 80% con¯uent monolayer of cells in 100 mm plates were washed with cold phosphate-buer saline (PBS) (140 mM NaCl, 2.6 mM KCl, 2 mM KH 2 PO 4 , 10 mM Na 2 HPO 4 , pH 7.4) and lysed in 1 ml of SDS Gel-Loading Buer (50 mM TrisCl, pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue, 10% glycerol). The samples were boiled for 5 min. The total cell lysates from various cell lines containing about 50 ± 100 mg protein each were fractionated using 7.5% polyacrylamide SDS gels. Following electrophoresis, the proteins in gels were then electro-transferred onto Trans Blot R nitrocellulose membranes (Bio-Rad) and subjected to Western blot analysis with the anity puri®ed anti-M2 antibodies. Brie¯y, the blot was ®rst incubated with 5% milk solution in TBS (50 mM TrisHCl, pH 7.5, 150 mM NaCl) for 30 min, and then incubated for 2 ± 4 h at room temperature or at 48C overnight with 1/100 dilution of the antibodies. The dilutions were made in TBS with 1% dry milk and 0.1% NaN 3 . The membranes were then washed in TBS with 0.05% Tween-20 for three times, 5 min each. Secondary antibodies (1/5000 dilution, goat anti-rabbit IgG, conjugated with horseradish peroxidase) were added and incubated at room temperature for another hour. The membranes were then washed ®ve times with TBS containing 0.05% Tween-20 soaked in Chemiluminescent reagent from Pierce (Rockford, IL, USA) and exposed to ®lms. The blots were then stripped and blotted with antidynamin antibodies as above to estimate amount of protein loaded.
Immunostaining of ovarian normal and tumor tissue sections
A set of 26 formalin-®xed, paran-embedded ovarian carcinoma and ®ve tissue blocks of ovaries without tumors were sectioned in 5 mm sheets and were studied by immunostaining to examine the presence of Dab2 protein expression. Both anity-puri®ed polyclonal anti-M2 and monoclonal anti-p96 antibodies were used, and similar staining pattern was obtained. The section were dewaxed with xylene, rehydrated in serial dilutions of alcohol, and steamed for 20 min in 30 mM citrate buer, pH 4.8 (Sigma), for antigen retrieval. The Level2 USA TM Multi-Species, Streptavidin-Biotin, Detection-System, which uses horseradish peroxidase (HRP) as conjugated enzyme and 3,3'-diaminobenzidine (DAB) as chromogen, was utilized according to the manufacturer's protocol with minor modi®cations. Brie¯y, after rinsing in PBS and blocking in 3% hydrogen peroxide for 5 min, the sections were washed in PBS with 0.5% Tween-20 three times, and blocked for 30 min in 5% normal goat serum provided in the kit. The slides were then incubated with 1 : 100 or 1 : 200 dilutions of the anitypuri®ed antibodies (25 mg/ml stock) in 10% bovine serum albumin (BSA) in PBS for 30 min at room temperature or overnight at 48C. Following three washes with PBS and 0.5% Tween-20, the sections were incubated with avidin-biotinylated enzyme complex for 30 min and washed as above. Finally, the sections were incubated with DAB for 15 ± 30 min, and washed three times in deionized water. The sections were counterstained with Mayer's hematoxylin for 1 ± 3 min, washed in tap water and incubated in PBS till blue. The stained sections were mounted with aqueous permanent mounting medium from Dako Corporation (Carpinteria, CA, USA), and covered with glass slips. All incubations were performed in humidi®ed chamber. Normal breast sections were used as positive controls in all staining. Primary antibody was replaced by 10% BSA in buer in negative controls. The M2 peptide (20 mM) was used to compete for the primary antibody to demonstrate the antibody-speci®c staining. Both manual and TechMate automated staining procedures were performed to optimize the staining conditions. The slides were read by at least three persons, including a pathologist (Dr C Cohen).
Measurement of mRNA
Human Dab2 cDNA was isolated using a fragment of the mouse Dab2 cDNA as a probe to screen a human testis cDNA library. The sequence of this cDNA fragment is identical to the reported human sequence (Albertsen et al., 1996) . Using this isolated Dab2 cDNA as template, a 0.4 kb fragment was ampli®ed using a pair of primers hPN (5'cccatccatgcactcctct3') and hPC (5'ctcaaatgcattgtcagtagat3'). This 0.4 kb fragment was gel-puri®ed and used as a probe for Northern blot analysis of human Dab2 mRNA from cells and tissues.
Total RNA was isolated from breast and ovarian tissues or cell lines by homogenization of the cell pellets or minced tissues with QIAshredder TM kit, followed by extraction with the RNeasy kit (Qiagen). Ethanol precipitated RNA (10 ± 20 mg) was dissolved in 5 ml Diethylpyrocarbonate (DEPC) water, heated at 658C for 15 min, and chilled on ice. Aliquots, 15 ml of RNA gel mix (mixture of 35 ml 37% formaldehyde, 100 ml redistilled formamide, and 20 ml of standard buer, pH 7.0, containing 0.2 M MOPS, 50 mM sodium acetate, and 10 mM EDTA) and 2 ml of gel loading dye were added. The mixture was then loaded and separated on 1% agarose, 7.4% formaldehyde gel in buer containing 20 mM MOPS), 5 mM sodium acetate (pH 8.0), 1 mM EDTA and 1/5 (v/v) of 37% formaldehyde for 5 h at 50 volts. The gel was stained with ethidium bromide to visualize the RNA as an indication of RNA amount loaded. The gel was washed in several changes of deionized water and ®nally rinsed in 26Standard Saline-Citrate (SSC) solution (0.3 M NaCl, 30 mM sodium citrate, pH 7.2). RNA was blotted onto Hybond TM -N+ nylon membranes (Amersham) overnight by capillary transfer using 16SSC. The blots were hybridized with the human 0.4 kb Dab2 cDNA probe labeled with digoxigenin epitope using the Genius Nucleic Acid Labeling and Detection Kit (Boehringer Mannheim). Signals were visualized by chemiluminescence according to the manufacturer's protocol. In some experiments, the blots were hybridized with probe labeled with a-32 P-dCTP using Oligolabelling kit (Pharmacia Biotech) and incubated for 45 min at 378C. After incubation, 200 ml of TrisHCl:EDTA buer (10 mM TrisCl, 1 mM EDTA, pH 8.0), 6 ml of 100 mM spermine and 6 ml of sheared salmon sperm DNA (10 mg/ml) was added and the mixture was chilled at 7208C for 5 min. After centrifugation for 10 min, the pellet was collected, dissolved, and incubated at 378C for 10 min in 200 ml of denature solution (5 M NaCl, 4 M NaOH and 0.1 M EDTA). An aliquot (38 ml) of neutralizing solution (2 M TrisCl, pH 8.0) was added and mixed thoroughly.
Blots were prehybridized in 15 ml Hybridsol I from Oncor (Gaithersburg, MD, USA) and then were hybridized in the same solution with 1 ± 6610 6 c.p.m./ml labeled probes for 18 h at 478C. Blots were washed three times with 0.1% SDS in 26SSC, and 0.1% SDS in 0.26SSC at 508C for 30 min. The signal was detected by autoradiography.
Abbreviations DAB, 3,3'-diaminobenzidine; DMEM, Dulbeco's modi®ed Eagle's Medium; DEPC, Diethylpyrocarbonate; DOC-2, Dierentially expressed in Ovarian Carcinomas 2; EGF, Epidermal Growth Factor; FBS, fetal bovine serum; Grb2, Growth Factor Receptor Binding Protein 2; MOPS, 3-morpholinopropane sulphonic acid; PRD, proline-rich domain; PID, phosphotyrosine interaction domain, or PTB; SH2 & SH3, Src homology domain 2 & 3; SDS, sodium dodicial sulphate; Sos, Son of Sevenless.
